2026 SPS Denver | Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma - A Review of Phase III IRAKLIA Study
0% Complete
Course Overview
NA
Course Content
Course Details
- Duration
- 0.00 hour
- Released
- May 23, 2026
- Last Review
- May 23, 2026
- Expires
- May 23, 2029
Objectives
NA
Target Audience
Pharmacists
Faculty & Disclosure
Faculty
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE
Disclosure
NA
Accreditation
NA
